Study of new biomarkers predicting early kidney damage associated with the use of potassium bromide and phenobarbital in epileptic canines
DOI:
https://doi.org/10.29155/VET.61.224.6Keywords:
Early diagnostic methods, New kidney biomarkers, Antiepileptic treatmentsAbstract
Epilepsy is a neurological disease present in a wide range of mammals, including humans and domestic canines and felines. The most commonly used pharmacological treatments for canines are phenobarbital and potassium bromide (KBr). However, both of these medications are partially eliminated through the kidneys, which could potentially cause damage at this level. Current diagnostic methods for kidney damage typically identify issues only at advanced stages, highlighting the need for early detection techniques. Thus, this study aims to evaluate early renal alterations in canines diagnosed with idiopathic epilepsy and treated with phenobarbital and/or KBr, using specific biomarkers such as kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL), alongside non-specific biomarkers such as C-reactive protein (C-RP). Data from 39 canines treated at the Veterinary Hospital Centre (Udelar) and private clinics in Montevideo, Uruguay, were analysed. Subjects were categorised into two groups: a control group (healthy animals) and a group of subjects previously diagnosed with idiopathic epilepsy. The latter group was subdivided into three additional groups: one treated with phenobarbital, one treated with phenobarbital/KBr, and one treated with KBr alone. Laboratory results were evaluated for new biomarkers and conventional analytes. No alterations were found in laboratory tests for liver function, profiles, or urinalysis among the 30 canines subjected to the different treatments. Regarding specific biomarkers, no statistically significant differences (p > 0.05) were observed among the groups. However, alterations in C-RP were found in the group treated only with KBr. Under the conditions of the trial, no significant changes were detected in urinalysis or renal profiles associated with the administration of phenobarbital and/or potassium bromide in canines with idiopathic epilepsy.
Downloads
Metrics
References
Armaşu, M., Packer, R., Cook, S., Solcan, G., & Volk, H. (2014). An exploratory study using a statistical approach as a platform for clinical reasoning in canine epilepsy. Journal of Veterinary Science, 202(2), 292-296. https://doi.org/10.1016/j.tvjl.2014.08.008
Baird-Heinz, H. E., Van Schoick, A. L., Pelsor, F. R., Ranivand, L., & Hungerford, L. L. (2012). A systematic review of the safety of potassium bromide in dogs. Journal of the American Veterinary Medical Association, 240(6), 705-715. https://doi.org/10.2460/javma.240.6.705
Bhatti, S. F., De Risio, L., Muñana, K., Penderis, J., Stein, V. M., Tipold, A., Berendt, M., Farquhar, R. G., Fischer, A., Long, S., Löscher, W., Mandigers, P. J., Matiasek, K., Pakozdy, A., Patterson, E. E., Platt, S., Podell, M., Potschka, H., Rusbridge, C., & Volk, H. A. (2015). International Veterinary Epilepsy Task Force consensus proposal: Medical treatment of canine epilepsy in Europe. BMC Veterinary Research, 11, 176-191. https://doi.org/10.1186/s12917-015-0464-z
Caspi, D., Snel, J., Batt, R., Bennett, D., Rutteman, G., Hartman, E. G., Baltz, M. L., Gruys, E., & Pepys, M. B. (1987). C-reactive protein in dogs. American Journal of Veterinary Research, 48(6), 919-921. https://doi.org/10.2460/ajvr.1987.48.06.919
Di Bartola, S., & Westropp, J. (2020). Trastornos del sistema urinario. En R. Nelson & C. Couto (Eds.), Medicina interna de pequeños animales (6.ª ed., pp. 649-679). Elsevier.
Ernst, R., Ogeer, J., McCrann, D., Cross, J., Strong-Townsend, M., Friis, H., Coyne, M., Clements, C., Drake, C., & Murphy, R. (2018). Comparative performance of IDEXX SDMA Test and the DLD SDMA ELISA for the measurement of SDMA in canine and feline serum. PLoS One, 13(10), e0205030. https://doi.org/10.1371/journal.pone.0205030
Feijoo, F., Ricart, M., Marina, L., Passeri, M., & Suraniti, A. (2020). Vómito, sialorrea y regurgitación como signos clínicos de convulsiones epilépticas focales autonómicas en tres perros. Revista Veterinaria, (41), 107-113. https://doi.org/10.19052/mv.vol1.iss41.10
Goiz-Márquez, G., Solís, H., Caballero, S., & Sumano, H. (2008). Epilepsia en perros. Veterinaria México Journal, 39(3), 279-321. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0301-50922008000300005&lng=es&tlng=es
Hammer, O., Harper, D., & Ryan, P. (2001). PAST: Paleontological Statistics software package for education and data analysis. Palaeontologia Electronica, 4(1), 4.
Han, W., Bailly, V., Abchandani, R., Thadhani, R., & Bonventre, J. (2002). Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney International, 62, 237-244. https://doi.org/10.1046/j.1523-1755.2002.00433.x
Harjen, H. J., Nicolaysen, T. V., Negard, T., Lund, H., Sævik, B. K., Anfinsen, K. P., Moldal, E. R., Zimmer, K. E., & Rørtveit, R. (2021). Serial serum creatinine, SDMA and urinary acute kidney injury biomarker measurements in dogs envenomated by the European adder (Vipera berus). BMC Veterinary Research, 17, 154. https://doi.org/10.1186/s12917-021-02851-8
Ichimura, T., Asseldonk, E. J., Humphreys, B. D., Gunaratnam, L., Duffield, J. S., & Bonventre, J. V. (2008). Kidney injury molecule–1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. Journal of Clinical Investigation, 118(5), 1657-1668. https://doi.org/10.1172/JCI34487
Joyce, D., Matz, L., & Saker, B. (1985). Renal failure and upper urinary tract obstruction after retrograde pyelography with potassium bromide solution. Human Toxicology, 4(5), 481-490. https://doi.org/10.1177/096032718500400504
Kielstein, J., Salpeter, S., Bode-Boeger, S., Cooke, J., & Fliser, D. (2006). Symmetric dimethylarginine (SDMA) as endogenous marker of renal function: A meta-analysis. Nephrology Dialysis Transplantation, 21, 2446-2451. https://doi.org/10.1093/ndt/gfl292
Lippi, I., Perondi, F., Meucci, V., Bruno, B., Gazzano, V., & Guidi, G. (2018). Clinical utility of urine kidney injury molecule-1 (KIM-1) and gamma-glutamyl transferase (GGT) in the diagnosis of canine acute kidney injury. Veterinary Research Communications, 42(2), 95-100. https://doi.org/10.1007/s11259-018-9711-7
Lu-Steffes, M., Pittluck, G. W., Jolley, M. E., Panas, H. N., Olive, D. L., Wang, C.-H., Nystrom, D. D., Keegan, C. L., Davis, T. P., & Stroupe, S. D. (1982). Fluorescence polarization immunoassay IV. Determination of phenytoin and phenobarbital in human serum and plasma. Clinical Chemistry, 28(11), 2278-2282. https://doi.org/10.1093/clinchem/28.11.2278
Metairon, S., Zamboni, C., Kovacs, L., Genezini, F., Santos, N., & Vilela, E. C. (2009). Analysis of elements in human blood of patients with chronic kidney disease using neutron activation analysis. Journal of Radioanalytical and Nuclear Chemistry, 282(1), 81-84. https://doi.org/10.1007/s10967-009-0272-7
Miguel, C., Giménez, M., & Meder, A. (2021). Neutrophil gelatinase-associated lipocalin (NGAL): Biomarker of acute kidney injury in dogs. Brazilian Journal of Veterinary Research and Animal Science, 4(2), 2490-2503. https://doi.org/10.34188/bjaerv4n2-076
Mishra, J., Dent, C., Tarabishi, R., Mitsnefes, M. M., Ma, Q., Kelly, C., Ruff, S. M., Zahedi, K., Shao, M., Bean, J., Mori, K., Barasch, J., & Devarajan, P. (2005). Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. The Lancet, 365(9466), 1231-1238. https://doi.org/10.1016/S0140-6736(05)74811-X
Muñana, K. (2013). Update seizure management in small animal practice. Veterinary Clinics of North America: Small Animal Practice, 43(5), 1127-1147. https://doi.org/10.1016/j.cvsm.2013.04.008
Nabity, M., & Hokamp, J. (2023). Urinary biomarkers of kidney disease in dogs and cats. Veterinary Clinics: Small Animal Practice, 53, 53-71. https://doi.org/10.1016/j.cvsm.2022.07.006
Noemi, I. (1999). Eosinofilia y parasitosis. Revista Chilena de Pediatría, 70(5), 435-440. https://doi.org/10.4067/S0370-41061999000500013
Parra, M., Cabezas-Herrera, J., & Cerón, J. (2005). Comparación de dos métodos para el aislamiento y purificación de la proteína C-reactiva (CRP) canina. Revista Científica de la Universidad de Murcia, 21, 139-149. https://revistas.um.es/analesvet/article/view/2791
Pérez-Sánchez, A., Perini-Perera, S., Del-Angel-Caraza, J., & Quijano-Hernández, I. (2023). Correlation of renal function biomarkers in the first diagnostic approach to canine chronic kidney disease. Journal MVZ Córdoba, 28(1), e2782. https://doi.org/10.21897/rmvz.2782
Perini, S., Pérez, A., Del-Ángel, J., Quijano, A., & Recillas, S. (2021). Evaluation of chronic kidney disease progression in dogs with therapeutic management of risk factors. Frontiers in Veterinary Science, 5, 621084. https://doi.org/10.3389/fvets.2021.621084
Podell, M. (2013). Antiepileptic drug therapy and monitoring. Topics in Companion Animal Medicine, 28, 59-66. https://doi.org/10.1053/j.tcam.2013.06.009
Potschka, H., Fischer, A., Löscher, W., Patterson, N., Bhatti, S., Berendt, M., De Risio, L., Farquhar, R., Long, S., Mandigers, P., Matiasek, K., Muñana, K., Pakozdy, A., Penderis, J., Platt, S., Podell, M., Rusbridge, C., Stein, V., Tipold, A., & Volk, H. A. (2015). International Veterinary Epilepsy Task Force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy. BMC Veterinary Research, 11(1), 177-189. https://doi.org/10.1186/s12917-015-0465-y
Rebar, H. (2003). Leucocitos en Períodos de Salud y Enfermedad. En Interpretación del hemograma canino y felino (pp. 11-19). The Gloyd Group.
Reyes-Uribe, E., Hernández-Bedolla, M., Salazar-Flores, J., & Torres-Sánchez, D. (2022). La proteína KIM-1, un biomarcador asociado a la enfermedad renal. Revista Huasteca, 10(19), 20-27. https://doi.org/10.29057/esh.v10i19.8213
Robaina, D., Bentancur, V., Feijóo, G., Damián, J. P., & Suárez, G. (2020). Validation and clinical application of a spectrophotometric technique for the determination of potassium bromide in canine serum for the control of epilepsy. Journal of Pharmacy & Pharmacognosy Research, 8(6), 515-524. https://doi.org/10.56499/jppres20.875_8.6.515
Segev, G., Palm, C., LeRoy, B., & Cowgill, L. (2013). Evaluation of NGAL lipocalin as a marker of kidney injury. Journal of Veterinary Internal Medicine, 27(6), 1362-1367. https://doi.org/10.1111/jvim.12180
Soni, S. S., Cruz, D., Bobek, I., Chionh, C. Y., Nalesso, F., Lentini, P., de Cal, M., Corradi, V., Virzi, G., & Ronco, C. (2009). NGAL: A biomarker of acute kidney injury and other systemic conditions. International Urology and Nephrology, 42, 141-150. https://doi.org/10.1007/s11255-009-9608-z
Thomas, W. (2000). Idiopathic epilepsy in dogs. Veterinary Clinics of North America: Small Animal Practice, 30, 183-206. https://doi.org/10.1016/S0195-5616(00)50009-6
Van Logten, M., Wolthuïs, M., Rauws, A., & Kroes, R. (1973). Short-term toxicity study on sodium bromide in rats. Toxicology, 1(4), 321-327. https://doi.org/10.1016/0300-483X(73)90038-3
Wasung, M., Chawla, L., & Madero, M. (2015). Biomarkers of renal function, which and when. Clinica Chimica Acta, 438, 350-357. https://doi.org/10.1016/j.cca.2014.08.039
Yokota, T., Omachi, K., Suico, M. A., Kojima, H., Kamura, M., Teramoto, K., Kaseda, S., Kuwazuru, J., Shuto, T., & Kai, H. (2017). Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome. PLoS One, 12(9), e0183959. https://doi.org/10.1371/journal.pone.0183959
Zar, J. H. (2010). Biostatistical analysis (5th ed.). Prentice Hall.
Zheng, J. S., Jing-Nie, Zhu, T. T., Ruan, H. R., Xue-Wei, & Rui-Wu. (2019). Screening of early diagnostic markers of gentamicin-induced acute kidney injury in canines. Journal of Veterinary Research, 63(3), 405-411. https://doi.org/10.2478/jvetres-2019-0048
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sociedad de Medicina Veterinaria del Uruguay-Facultad de Veterinaria, Universidad de la República
This work is licensed under a Creative Commons Attribution 4.0 International License.
